Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sublingual Cannabis Tablets and Drops
NCT04261166Phase 1Completed
- Sponsor
- BOL Pharma
- Start
- Jul 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol and dronabinol in Autism Spectrum Disorder (ASD) and neuropathic pain (4 arms), sponsored by BOL Pharma. Primary endpoints: Maximum Plasma Concentration, Lag Time and 5 more. Started Jul 2019; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
Autism Spectrum Disorder (ASD)neuropathic pain
Beyond the preview
Go deeper on NCT04261166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261166.